Advertisement

Strategies for Treating Abnormal Lipid Profiles with Drugs

  • Neil J. Stone
Chapter

Abstract

For the past 50 years, cardiovascular diseases have been the leading killers of men and women in the industrialized world [1]. A major advance has been ­control of risk factors, habits, or traits that incline susceptible individuals to coronary heart disease (CHD). Prospectively gathered data from the Framingham Heart Study shows that for men and women who at age 50 have no major risk factors, the burden of CHD is very small [2]. However, for those who reach 50 years of age with risk factors, the event rates for CHD with a reduction in total life expectancy is correspondingly large. Not surprisingly, for those who have already sustained a coronary event, cardiovascular mortality in the absence of treatment is high. Analysis of published studies by Law et al. [3] showed that the rate, if untreated, is 5% per year after a first myocardial infarction (MI) and 10% per year after each subsequent MI. There is consistent evidence from multiple, randomized, placebo-controlled clinical trials (RPCCTs) that the treatment of elevated blood cholesterol, a major CHD risk factor, results in a clinically important outcome difference. For patients who have known CHD or are greatly at its risk, treatment with HMG Coa reductase inhibitors (statins) that lower low-density lipoprotein cholesterol (LDL-C) substantially (more than 30%) is associated with significant reductions in fatal and nonfatal CHD [4,5].

Keywords

Coronary Heart Disease Coronary Heart Disease Risk Factor Cholesterol Absorption Inhibitor Total Life Expectancy High Dose Statin Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    American Heart Association: American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2009 update. Circulation 2009, 119:480–486.Google Scholar
  2. 2.
    Lloyd-Jones DM, Leip EP, Larson MG, et al.: Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791–798.PubMedGoogle Scholar
  3. 3.
    Law MR, Watt HC, Wald NJ: The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med 2002, 162:2405–2410.PubMedGoogle Scholar
  4. 4.
    National Heart Lung and Blood Institute: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III final report. Circulation 2002, 106:3143–421.Google Scholar
  5. 5.
    Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004, 110:227–239.PubMedGoogle Scholar
  6. 6.
    Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994, 344:1383–1389.Google Scholar
  7. 7.
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.Google Scholar
  8. 8.
    Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk ­individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.Google Scholar
  9. 9.
    Stone NJ, Blum C: Management of Lipids in Clinical Practice, edn 7, Caddo, OK: Professional Communications; 2008.Google Scholar
  10. 10.
    Bradford RH, Shear CL, Chremos AN, et al.: Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991, 151:43–49.PubMedGoogle Scholar
  11. 11.
    Cannon CP, Braunwald E, McCabe CH, et al.: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504.PubMedGoogle Scholar
  12. 12.
    Davidson MH, Robinson JG: Safety of aggressive lipid management. J Am Coll Card 2007, 49:1753–1762.Google Scholar
  13. 13.
    Law M, Wald N, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423–1430.PubMedGoogle Scholar
  14. 14.
    Ridker P, Danielson E, Fonseca FA, et al.: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). N Engl J Med 2008, 359:2195–2207.PubMedGoogle Scholar
  15. 15.
    Schonbeck U, Gerdes N, Varo N, et al.: Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002, 106:2888–2893.PubMedGoogle Scholar
  16. 16.
    Tamai O, Matsuoka H, Itabe H, et al.: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76–82.PubMedGoogle Scholar
  17. 17.
    Davignon J: Beneficial pleiotropic effects of statins. Circulation 2004, 109(Suppl III):III-39–III-43.Google Scholar
  18. 18.
    LaRosa J, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352: 1425–1435.PubMedGoogle Scholar
  19. 19.
    Nakamura H, Arakawa K, Itakura H et al.: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 2006, 368:1155–1163.PubMedGoogle Scholar
  20. 20.
    Mizuno K, Nakaya N, Ohashi Y, et al.: Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation 2008, 117:494–502.PubMedGoogle Scholar
  21. 21.
    Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264–1272.PubMedGoogle Scholar
  22. 22.
    Berry JD, Liu K, Folsom AR, et al.: Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation 2009, 119:382–389.PubMedGoogle Scholar
  23. 23.
    Grundy SM: Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am J Cardiol 1995, 75:45B–52B.PubMedGoogle Scholar
  24. 24.
    Leroux G, Lemieux I, Lamarche B, et al.: Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels. Metabolism 2000, 49:53–61.PubMedGoogle Scholar
  25. 25.
    Ballantyne CM, Andrews TC, Hsia JA, et al.: Correlation of non–high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non–high-density lipoprotein cholesterol levels. Am J Cardiol 2001, 88: 265–269.PubMedGoogle Scholar
  26. 26.
    Brewer HB: Increasing HDL cholesterol levels. N Engl J Med 2004, 350:1491–1494.PubMedGoogle Scholar
  27. 27.
    Pasternak RC, Smith SC, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. JACC 2002, 40:567–572.PubMedGoogle Scholar
  28. 28.
    Herd JA, Ballantyne CM, Farmer JA, et al.: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations. (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997, 80:278–286.PubMedGoogle Scholar
  29. 29.
    Holdaas H, Fellström B, Jardine AG, et al. on behalf of the Assessment of LEscol in Renal Transplantation (ALERT) Study investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024–2031.PubMedGoogle Scholar
  30. 30.
    Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998, 279:1615–1622.PubMedGoogle Scholar
  31. 31.
    Blankenhorn DH, Azen SP, Kramsch DM, et al.: The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993, 119:969–976.PubMedGoogle Scholar
  32. 32.
    The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 1997, 336:153–162.Google Scholar
  33. 33.
    Waters D, Higginson L, Gladstone P, et al.: Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative angiography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994, 89:959–968.PubMedGoogle Scholar
  34. 34.
    Furberg CD, Adams HP Jr, Applegate WB, et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994, 90:1679–1687.PubMedGoogle Scholar
  35. 35.
    Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301–1307.PubMedGoogle Scholar
  36. 36.
    ALLHAT investigators: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLA). JAMA 2002, 288:2998–3007.Google Scholar
  37. 37.
    Jukema JW, Bruschke AV, van Boven AJ, et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study. Circulation 1995, 91:2528–2540.PubMedGoogle Scholar
  38. 38.
    Pitt B, Mancini GB, Ellis SG, et al.: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC-I investigation. J Am Coll Cardiol 1995, 26:1133–1139.PubMedGoogle Scholar
  39. 39.
    Mercuri M, Bond MG, Sirtori CR, et al.: Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996, 101: 627–634.PubMedGoogle Scholar
  40. 40.
    Salonen R, Nyyssonen K, Porkkala E, et al.: Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995, 92:1758–1764.PubMedGoogle Scholar
  41. 41.
    Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001–1009.PubMedGoogle Scholar
  42. 42.
    Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623–1630.PubMedGoogle Scholar
  43. 43.
    MAAS investigators: Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994, 344:633–638.Google Scholar
  44. 44.
    Sever PS, Dalhof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149–1158.PubMedGoogle Scholar
  45. 45.
    Calhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre, randomized, placebo controlled trial. Lancet 2004, 364:685–696.Google Scholar
  46. 46.
    Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711–1718PubMedGoogle Scholar
  47. 47.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080.PubMedGoogle Scholar
  48. 48.
    Ballantyne CM, Raichlen JS, Nicholls SJ, et al.: Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography. Circulation 2008, 117:2458–2466.PubMedGoogle Scholar
  49. 49.
    Ballantyne CM, Corsini A, Davidson MH, et al.: Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003, 163:553–564.PubMedGoogle Scholar
  50. 50.
    Phillips PS, Haas RH, Bannykh S, et al.: Statin-associated myopathy with normal creatine kinase levels. The Scripps Mercy Clinical Research Center. Ann Intern Med 2002, 137:581–585.PubMedGoogle Scholar
  51. 51.
    Thompson PD, Zmuda JM, Domalik LJ, et al.: Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997, 46:1206–1210.PubMedGoogle Scholar
  52. 52.
    Werba JP, Giroli M, Cavalca, V, et al.: The effect of green tea on simvastatin tolerability. Ann Int Med 2008, 149:286–287.PubMedGoogle Scholar
  53. 53.
    Kantola T, Backman JT, Niemi M, et al.: Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000, 56:225–259.PubMedGoogle Scholar
  54. 54.
    Cooper KJ, Martin PD, Dane AL, et al.: The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002, 58:527–531.PubMedGoogle Scholar
  55. 55.
    Westergren T, Johansson P, Molden E: Probable warfarin-simvastatin interaction. Ann Pharmacother 2007, 41:1292–1295.PubMedGoogle Scholar
  56. 56.
    Alsheikh-Ali AA, Karas RH: Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidiones. Am J Card 2004, 93:1417–1418.PubMedGoogle Scholar
  57. 57.
    Amarenco P, Bogousslavsky J, Callahan A 3rd, et al.: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549–559.PubMedGoogle Scholar
  58. 58.
    O’Keefe JH, Cordain L, Harris WH, et al.: Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004, 43:2142–2146.PubMedGoogle Scholar
  59. 59.
    Miettinen TA, Strandberg TE, Gylling H: Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 2000, 20:1340–1346.PubMedGoogle Scholar
  60. 60.
    Knapp HH, Schrott H, Ma P, et al.: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001, 110:352–360.PubMedGoogle Scholar
  61. 61.
    Hunninghake D, Insull W Jr, Toth P, et al.: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001, 158:407–416.PubMedGoogle Scholar
  62. 62.
    Ballantyne CM, Houri J, Notarbartolo A, et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107:2409–2415.PubMedGoogle Scholar
  63. 63.
    Turley SD: Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin Cardiol 2004, 27(Suppl 3):III16–III21.PubMedGoogle Scholar
  64. 64.
    Jacobson TA, Armani A, McKenney JM, Guyton JR: Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007, 99:47C–55C.PubMedGoogle Scholar
  65. 65.
    Buchwald H, Varco RL, Boen JR, et al.: Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH (Program on the Surgical Control of the Hyperlipidemias). Arch Intern Med 1998, 158:1253–1261.PubMedGoogle Scholar
  66. 66.
    Kastelein JJ, Akdim F, Stroes ES, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431–1443.PubMedGoogle Scholar
  67. 67.
    Fleg JL, Mete M, Howard BV, et al.: Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008, 52:2198–2205.PubMedGoogle Scholar
  68. 68.
    Rossebø AB, Pedersen TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343–1356.PubMedGoogle Scholar
  69. 69.
    Gagne C, Gaudet D, Bruckert E, Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469–2475.PubMedGoogle Scholar
  70. 70.
    Salen G, von Bergmann K, Lutjohann D, et al.: Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004, 109:966–971.PubMedGoogle Scholar
  71. 71.
    Peto R, Emberson J, Landray M, et al.: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008, 359:1357–1356.PubMedGoogle Scholar
  72. 72.
    Brown WV, Goldberg AC, Guyton JR, Knopp RH: Clinical lipidology roundtable discussion. The use of niacin. J Clin Lipidol 2009, 3:65–69.Google Scholar
  73. 73.
    Kamanna VS, Kashyap ML: Mechanism of action of niacin. Am J Cardiol 2008, 101:20B–26B.PubMedGoogle Scholar
  74. 74.
    Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.PubMedGoogle Scholar
  75. 75.
    Asztalos BF, Batista M, Horvath KV, et al.: Change in {alpha}1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003, 23:847–852.PubMedGoogle Scholar
  76. 76.
    Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245–1255.PubMedGoogle Scholar
  77. 77.
    Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of interim lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289–1298.PubMedGoogle Scholar
  78. 78.
    Cheung MC, Zhao XQ, Chait A, et al.: Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001, 21:1320–1326.PubMedGoogle Scholar
  79. 79.
    Maher VM, Brown BG, Marcovina SM, et al.: Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995, 274:1771–1774.PubMedGoogle Scholar
  80. 80.
    Elam MB, Hunninghake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study, a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284:1263–1270.PubMedGoogle Scholar
  81. 81.
    Martin-Jadraque R, Tato F, Mostaza JM, et al.: Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med 1996, 156:1081–1088.PubMedGoogle Scholar
  82. 82.
    Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097–1104.PubMedGoogle Scholar
  83. 83.
    Guyton JR, Capuzzi DM: Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 1998, 82:82U–84U.PubMedGoogle Scholar
  84. 84.
    Grundy SM, Vega GL, McGovern ME, et al.: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med 2002, 162:1568–1576.PubMedGoogle Scholar
  85. 85.
    McKinney J: New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004, 164:697–705.Google Scholar
  86. 86.
    Carlson LA, Rosenhamer G: Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1998, 223:405–418.Google Scholar
  87. 87.
    Blankenhorn DH, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987, 257:3233–3240.PubMedGoogle Scholar
  88. 88.
    Kane JP, Malloy JM, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264:3007–3012.PubMedGoogle Scholar
  89. 89.
    Staels B, Dallongeville J, Auwerx J, et al.: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088–2093.PubMedGoogle Scholar
  90. 90.
    The ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010 Mar 18 (Epub ahead of print).Google Scholar
  91. 91.
    Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998, 34:155–162.PubMedGoogle Scholar
  92. 92.
    Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849–1861.PubMedGoogle Scholar
  93. 93.
    Prueksaritanont T, Tang C, Qiu Y, et al.: Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002, 30:1280–1287.PubMedGoogle Scholar
  94. 94.
    Niemi M, Backman JT, Neuvonen M, Neuvonen PJ: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003, 46:347–351.PubMedGoogle Scholar
  95. 95.
    Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237–1245.PubMedGoogle Scholar
  96. 96.
    Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410–418.PubMedGoogle Scholar
  97. 97.
    Robins SJ, Rubins HB, Faas FH, et al.: Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the VA-HIT. Diabetes Care 2003, 26:1513–1517.PubMedGoogle Scholar
  98. 98.
    The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21–27.Google Scholar
  99. 99.
    DAIS Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905–910.Google Scholar
  100. 100.
    Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747–2757.PubMedGoogle Scholar
  101. 101.
    Harris WS, Miller M, Tighe AP, et al.: Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008, 197:12–24.PubMedGoogle Scholar
  102. 102.
    Burr ML, Fehily AM, Gilbert JF, et al.: Effects of changes in fat, fish and fibre intakes on death and myocardial infarction: diet and reinfarction trial (DART). Lancet 1989, 2:757–761.PubMedGoogle Scholar
  103. 103.
    GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E in 11,324 patients with myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354:447–455.Google Scholar
  104. 104.
    de Lorgeril M, Renaud S, Mamelle N, et al.: Mediterranean alpha linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994, 343:1454–1459.PubMedGoogle Scholar
  105. 105.
    Brouwer IA, Raitt MH, Dullemeijer C, et al.: Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J 2009, 7:820–826.Google Scholar
  106. 106.
    Harris WS, Mozaffarian D, Lefevre M, et al.: Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 2009, 139:804S–819S.PubMedGoogle Scholar
  107. 107.
    Manson JE, Skerrett PJ, Greenland P, VanItallie TB: The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med 2004, 164:249–258.PubMedGoogle Scholar
  108. 108.
    Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419–1424.PubMedGoogle Scholar
  109. 109.
    Yusuf S, Pais P, Afzal R, et al.: Effects of a polypill on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009, 373:1341–1351.PubMedGoogle Scholar
  110. 110.
    Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403–14.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Neil J. Stone
    • 1
  1. 1.Department of Cardiology, Center for Vascular Disease, Feinberg School of MedicineNorthwestern University, Bluhm Cardiovascular Institute, Northwestern Memorial HospitalChicagoUSA

Personalised recommendations